The FDA Center for Devices and Radiological Health (CDRH) will accept applications for the FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder (“the Challenge”) from June 1, 2018, through September 30, 2018. Medical devices that lead to the prevention and treatment of opioid use disorder are desired, and their developers are encouraged to apply. Developers of currently marketed devices who are interested in demonstrating that their device has an improved benefit-risk profile as compared to opioids in the management of pain, may also apply.
Applicants selected for the Challenge will work directly with the FDA to accelerate the development and eventual review of marketing applications for innovative products, similar to what occurs under the Breakthrough Devices Program. In addition, Breakthrough Device designation will be granted to those devices that meet the statutory criteria for designation without submission of a separate application.
Proposals submitted will be evaluated based on the feasibility, potential public health impact, and novelty of the concept. The number of proposals selected into the Challenge will be determined by the quality of applications received and available FDA resources. The FDA intends to announce applications selected for the Challenge in November 2018.
The criteria for selection, application instructions, and additional information can be found here.
Learn more about the Challenge in a webinar on July 25
What: Webinar to learn about a new FDA innovation funding program.
When: Wednesday, July 25, 2018, 1:00 pm Eastern Time
How: No registration is necessary.
To hear the presentation and ask questions:
- Dial: 888-282-0360; International Callers Dial: 1-630-395-0147; Conference Number: PWXW7562309; Passcode: 2848432
- To view the slide presentation during the webinar: https://www.mymeetings.com/nc/join.php?i=PWXW7562309&p=2848432&t=c
- Following the webinar, a transcript, audio recording, and slides will be available at: https://www.fda.gov/CDRHWebinar. The slide presentation will also be available at this site on the morning of the webinar.